Perjeta/Herceptin (pertuzumab/trastuzumab)

pCPA File Number: 20814
Negotiation Status:
Negotiations were not pursued
Indication(s):
Neoadjuvant Breast Cancer
Sponsor/Manufacturer:
Hoffmann-La Roche Ltd.
CDA-AMC Project Number:
PC0050-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: